hydroxyurea and imatinib mesylate

hydroxyurea has been researched along with imatinib mesylate in 125 studies

Research

Studies (125)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	76 (60.80)	29.6817
2010's	44 (35.20)	24.3611
2020's	5 (4.00)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Druker, BJ; Kolibaba, KS; Ohno-Jones, S; Thiesing, JT	1
Fruehauf, S; Topaly, J; Zeller, WJ	1
Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S	1
Brunstein, CG; Mcglave, PB	1
Buchdunger, E; Druker, BJ; Matter, A	1
Burkland, GA; Schaller, JL	1
Gschaidmeier, H; Hoelzer, D; Klein, SA; Martin, H; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B	1
Andreeff, M; Arlinghaus, RB; Guo, JQ; Lin, H	1
Antman, KH; Savage, DG	1
Ault, P; Cortes, J; Kaled, ES; Kantarjian, H; Koller, C	1
Hochhaus, A; Lahaye, T; Müller, MC	1
Berger, U; Engelich, G; Helmann, R	1
Hentrich, M; Ledderose, G; Salat, C; Stoetzer, OJ	1
Hentrich, M; Salat, C; Stoetzer, OJ	1
Berger, U; Engelich, G; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Reiter, A	1
Liu, NS; O'Brien, S	1
Dalziel, K; Garside, R; Round, A; Royle, P; Stein, K	1
Dickinson, TM; Jones, CM	1
Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J	1
Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F	1
Drechsler, M; Haas, R; Herold, C; Hildebrandt, B; Kronenwett, R; Redmann, A; Royer-Pokora, B; Wieland, C	1
Goldman, JM	1
Rák, K	1
Hehlmann, R	1
Ehninger, G; Habermann, I; Kiani, A; Neubauer, A; Rogge, L; Schäke, K	1
Birgens, H; Bjerrum, OW; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Ralfkiaer, E; Therkildsen, MH	1
Berger, U; Hehlmann, R; Hochhaus, A; Lengfelder, E; Reiter, A	1
Engels, K; Griesshammer, M; Klose, J; Kriener, S; Kvasnicka, HM; Schmitt-Graeff, A; Staib, P; Thiele, J	1
Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T	1
Delgado, MD; Gómez-Casares, MT; Lemes, A; León, J; Molero, T; Vaqué, JP	1
Dalziel, K; Garside, R; Price, A; Round, A; Stein, K	1
Harrison, SJ; Holyoake, TL; Johnson, PR	1
Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C	1
Babu, KG; Bapsy, PP; George, J; Singhal, N	1
Campbell, PJ; Curtin, NJ; Green, AR	1
Bartlett, HM; Costakos, D; Mandava, N	1
Huang, Q	1
Dalziel, K; Garside, R; Round, A; Stein, K	1
Borbényi, Z	1
Dresemann, G	1
Chatterjee, T; Choudhry, DR; Choudhry, VP; Dixit, A; Kumar, R; Mahapatra, M; Mishra, P; Sazawal, S; Tyagi, S	1
Fay, M; Goldman, J; Murphy, PT; O'Donnell, R; Quinn, J; Swords, R	1
Alimena, G; Breccia, M; Muscaritoli, M	1
Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B	1
Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ	1
Binder, T; Esterbauer, H; Florian, S; Haas, OA; Müllauer, L; Sillaber, C; Sperr, WR; Valent, P	1
Charlanne, H; Prin, L	1
Bernardini, K; Buratti, T; Lanthaler, AJ; Mitterer, M	1
Dai, CW; Li, RJ; Liu, DS; Zhang, GS	1
Cabello, P; Cesar, JM; Ferro, T; Navarro, JL	1
Bruijnzeel-Koomen, CA; Lokhorst, HM; van Ruth, S	1
Batár, P; László, R; Telek, B; Udvardy, M	1
Assouline, S; Benemacher, V; Gambacorti-Passerini, C	1
Bihorel, S; Camenisch, G; Gross, G; Lemaire, M; Scherrmann, JM	1
Beijnen, JH; Marchetti, S; Mazzanti, R; Oostendorp, RL; Schellens, JH	1
Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ	1
DesJardins, A; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ	1
Alimena, G; Breccia, M; Gentilini, F	1
Grzybowski, G; Mikołajczyk, K; Samborski, W; Walkowiak, B; Zaba, R	1
Cheung, K; Kamel-Reid, S; Lipton, JH; Ostro, D	1
Abrey, LE; Gavrilovic, IT; Lassman, AB; Rosenfeld, SS; Shah, GD; Silver, JS	1
Cervantes, F	1
Dahabreh, IJ; Giannouli, S; Moutsopoulos, HM; Voulgarelis, M; Zoi, C; Zoi, K	1
Egyed, M; Karádi, E; Kollár, B; Matolcsi, A; Rajnics, P	1
Bornhäuser, M; Dresemann, G; Ehninger, G; Hosius, C; Illmer, T; Nikolova, Z; Prondzinsky, R; Pursche, S; Said, SM; Schleyer, E; von Bonin, M; Wang, Y	1
Bhargava, R; Dolai, TK; Mahapatra, M; Mishra, P; Pati, HP; Saxena, R; Seth, T	1
Butterfield, JH	1
Fink, GR; Galldiks, N; Kracht, LW; Schroeter, M; Ullrich, R	1
Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ	1
Cortes, J; Fava, C; Kantarjian, H; Verma, D	1
Jamedhor, M; Reddy, KS; Schwartz, GE	1
Dresemann, G; Engel, E; Fluge, O; Heinrich, B; Hosius, C; Karup-Hansen, A; Krex, D; Mayer-Steinacker, R; Mehdorn, M; Nikolova, Z; Nowak, A; Olver, IN; Parker, R; Rosenthal, MA; Schleyer, E; Sieder, C; Sorenson, G; Steinbach, JP; Wagner, W; Wedding, U; Weller, M	1
Chen, Y; Li, D; Li, S	1
Butterfield, JH; Li, CY; Lim, KH; Pardanani, A; Tefferi, A	1
Gotlib, J	1
Bergstrom, P; Blomquist, E; Campone, M; Clement, P; Dresemann, G; Easaw, J; Gijtenbeek, A; Gil, M; Gordower, L; Green, S; Hau, P; Nikolova, Z; Raizer, J; Reardon, DA; Schlegel, U; Schultz, H; Taillibert, S; Tonn, J; van den Bent, M; Weir, A	1
Bochner, BS; Butterfield, JH; Gleich, GJ; Huss-Marp, J; Kahn, JE; Klion, AD; Leiferman, KM; Nutman, TB; Ogbogu, PU; Pfab, F; Ring, J; Rothenberg, ME; Roufosse, F; Sajous, MH; Sheikh, J; Simon, D; Simon, HU; Stein, ML; Wardlaw, A; Weller, PF	1
Goto, H; Hara, Y; Kamura, Y; Mugishima, H; Oikawa, A; Shichino, H	1
Dresemann, G; Hasselblatt, M; Jarvius, M; Joensuu, H; Lindh, MB; Nistér, M; Nupponen, NN; Ostman, A; Paulsson, J; Paulus, W; Puputti, M; Söderberg, O; von Deimling, A	1
Imai, T; Machida, T; Shima, Y; Uemura, Y	1
Li, W; Lou, TF; Mackie, A; Pace, B; Ramakrishnan, V; Sivanand, S; Zein, S	1
Liang, MY; Wang, DP; Wang, SM; Zhang, XH	1
Hamšíková, E; Humlová, Z; Janatková, I; Klamová, H; Králíková, P; Malíčková, K; Roth, Z; Sterzl, I; Vonka, V	1
Barbagallo, I; Chiarenza, A; Conticello, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Romano, A; Stagno, F; Tibullo, D	1
Alfonso, G; Alú, MF; Belli, C; Bianchini, M; Larripa, I	1
Cheung, WY; Ksienski, D	1
Pardanani, A	1
Ben Youssef, Y; Bennour, A; Elloumi, M; Harrabi, I; Khelif, A; Laatiri, MA; Meddeb, B; Ouahchi, I; Saad, A; Sennana, H; Zaier, M	1
Cyriac, S; Dubashi, B; Ganesan, P; Kannan, K; Nandennavar, M; Rajendranath, R; Sagar, TG	1
Akaogi, T; Kawata, E; Kobayashi, Y; Tanaka, T	1
Lavanya, R; Sankar, J; Srinivasan, A	1
Guilhot, F; Roy, L; Tomowiak, C	1
Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY	1
Agarwal, JP; Banavali, S; Budrukkar, A; Chatturvedi, P; D'Cruz, A; Laskar, SG; Murthy, V; Muttagi, S; Shahid, T	1
Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ	1
Butterfield, JH; Weiler, CR	1
Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G	1
Borsky, M; Dvorakova, D; Jeziskova, I; Jurcek, T; Mayer, J; Racil, Z; Razga, F; Zackova, D	1
Cogan, E; Roufosse, F	1
Ghosh, B; Goel, N; Pangtey, B; Raina, UK; Thakar, M	1
Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT	1
Conte, E; Di Raimondo, F; Manzella, L; Stagno, F; Stella, S; Tirrò, E; Vigneri, P	1
Chaudhary, SC; Jain, N; Kumar, V; Mishra, S	1
Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Gjertsen, BT; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lotfi, K; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Remes, K; Richter, J; Simonsson, B; Söderlund, S; Stenke, L; Suominen, M	1
De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A	1
Ha, J; Jang, HM; Jung, DI; Jung, HW; Kim, JH; Lee, HC; Moon, JH; Sur, JH	1
Matsumura, I	1
Abdel-malek, RR; Edesa, WA	1
Roufosse, F	1
Balduzzi, A; Faraci, M; Ferretti, M; Giardino, S; Lanino, E; Matthes-Martin, S; Micalizzi, C; Morreale, G	1
Payandeh, M; Sadeghi, E; Sadeghi, M	1
Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S	1
Adam, T; Faber, E; Fikarová, I; Friedecký, D; Gardlo, A; Hrdá, M; Janečková, H; Karlíková, R; Mičová, K; Široká, J; Vrobel, I	1
Chen, L; Fangping, C; Huang, J; Qun, H; Wang, L; Xielan, Z; Yajing, X	1
Bi, L; Duan, J; Fan, Z; Pan, L; Qiao, W; Wu, D; Yang, M	1
Dmytrenko, IV; Dyagil, IS; Fedorenko, VG; Martina, ZV; Minchenko, ZM; Shlyakhtychenko, TY; Sholoyko, VV; Silayev, YO; Tovstogan, AO	1
Cattaneo, D; Gianelli, U; Iurlo, A	1
Harahap, A; Jusman, SW; Reksodiputro, AH; Rinaldi, I; Setiabudy, R; Suharti, C; Tambunan, K; Wanandi, SI	1
Abdullah, M; Al-Dubai, W; Al-Gharasi, L; Al-Ghazaly, J; Noaman, Y; Rosti, G	1
Ackermann, F; Étienne, N; Groh, M; Kahn, JE; Lefèvre, G	1
Hasegawa, G; Koda, R; Morita, S; Nagano, O; Seki, Y	1
Edao, A; Hailemariam, TS; Kinde, S; Mehdi, M; Seifu, D	1
Chen, LYC; Dou, C; Williams, AK	1
Errani, C; Mavrogenis, AF; Takahama, T; Tanaka, Y; Tsukamoto, S	1

Reviews

23 review(s) available for hydroxyurea and imatinib mesylate

Article	Year
The biology and treatment of chronic myelogenous leukemia. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Survival Analysis	2001
Bcr-Abl inhibition as a modality of CML therapeutics. Biochimica et biophysica acta, 2001, Aug-31, Volume: 1551, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured	2001
Imatinib mesylate--a new oral targeted therapy. The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance; Gastrointestinal Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma	2002
[Chronic myeloid leukemia--treatment]. Deutsche medizinische Wochenschrift (1946), 2002, Dec-06, Volume: 127, Issue:49 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Risk Factors; Stem Cell Transplantation	2002
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]. Der Internist, 2002, Volume: 43, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation	2002
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. Health technology assessment (Winchester, England), 2002, Volume: 6, Issue:33 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; United Kingdom	2002
Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia, 2003, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 2; Clinical Trials, Phase III as Topic; Clone Cells; Disease Progression; DNA-Binding Proteins; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Histone-Lysine N-Methyltransferase; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Philadelphia Chromosome; Piperazines; Proto-Oncogenes; Pyrimidines; Randomized Controlled Trials as Topic; Transcription Factors; Translocation, Genetic	2003
Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. Seminars in hematology, 2003, Volume: 40, Issue:1 Suppl 1 Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2003
[Current therapy of chronic myeloid leukemia]. Orvosi hetilap, 2003, Mar-02, Volume: 144, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Enzyme Inhibitors; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Stem Cell Transplantation	2003
Current CML therapy: progress and dilemma. Leukemia, 2003, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation	2003
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:28 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2004
Chronic myeloid leukemia. The Journal of the Association of Physicians of India, 2004, Volume: 52 Topics: Antineoplastic Agents; Benzamides; Busulfan; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation	2004
[Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Decision Trees; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2005
[Treatment of hypereosinophilia]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:1 Pt 2 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzamides; Chronic Disease; Cyclosporins; Drug Resistance; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Myeloproliferative Disorders; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Time Factors	2006
Myelofibrosis: biology and treatment options. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide	2007
Treatment of hypereosinophilic syndromes--the first 100 years. Seminars in hematology, 2012, Volume: 49, Issue:2 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antiviral Agents; Benzamides; CD52 Antigen; Glycoproteins; History, 20th Century; History, 21st Century; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Interleukin-5; Piperazines; Polyethylene Glycols; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins	2012
Clinical management of the hypereosinophilic syndromes. Expert review of hematology, 2012, Volume: 5, Issue:3 Topics: Adrenal Cortex Hormones; Antibodies; Benzamides; Enzyme Inhibitors; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Interleukin-5; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation	2012
[True polycythemia: current views of pathogenesis, diagnostics and treatment]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:8 Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hematocrit; Hemodilution; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myeloid, Acute; Mutation; Piperazines; Platelet Aggregation Inhibitors; Polycythemia Vera; Prevalence; Primary Myelofibrosis; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Thrombosis; Treatment Outcome	2012
[Treatment of chronic myeloid leukemia in chronic phase]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Translocation, Genetic	2014
Management of Hypereosinophilic Syndromes. Immunology and allergy clinics of North America, 2015, Volume: 35, Issue:3 Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia; mRNA Cleavage and Polyadenylation Factors; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha	2015
Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies). Expert review of hematology, 2019, Volume: 12, Issue:12 Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Imidazoles; Interferon-alpha; Precision Medicine; Pyridazines	2019
Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis. British journal of haematology, 2021, Volume: 195, Issue:5 Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Cyclosporine; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Interleukin-5; Lymphocyte Activation; Lymphocytes	2021
Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review. Musculoskeletal surgery, 2023, Volume: 107, Issue:1 Topics: Doxorubicin; Fibromatosis, Aggressive; Humans; Hydroxyurea; Imatinib Mesylate; Methotrexate; Sorafenib; Vinorelbine; Watchful Waiting	2023

Trials

16 trial(s) available for hydroxyurea and imatinib mesylate

Article	Year
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia, 2001, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2001
[Imatinib combination therapies--the new CML Study 4]. Deutsche medizinische Wochenschrift (1946), 2002, Oct-18, Volume: 127, Issue:42 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome	2002
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. American journal of hematology, 2003, Volume: 74, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukocytosis; Male; Middle Aged; Piperazines; Polycythemia; Primary Myelofibrosis; Pyrimidines; Thrombocytosis; Treatment Outcome	2003
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome	2005
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis	2005
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of neuro-oncology, 2007, Volume: 83, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. Journal of neuro-oncology, 2007, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Synthesis Inhibitors; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome	2007
Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine, 2007, Volume: 86, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetic Analysis; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Patient Selection; Piperazines; Prednisone; Prospective Studies; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Translocation, Genetic	2007
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, May-15, Volume: 115, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome	2009
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-oncology, 2010, Volume: 96, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Temozolomide; Treatment Outcome; Young Adult	2010
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British journal of cancer, 2009, Dec-15, Volume: 101, Issue:12 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Brain Neoplasms; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Rate	2009
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. International journal of cancer, 2011, Apr-15, Volume: 128, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylation; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate	2011
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of neuro-oncology, 2012, Volume: 106, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Pyrimidines	2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer, 2012, Oct-01, Volume: 118, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome	2012
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). European journal of haematology, 2015, Volume: 94, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; Survival Analysis; Thiazoles	2015
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome	2016

Other Studies

86 other study(ies) available for hydroxyurea and imatinib mesylate

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 2000, Nov-01, Volume: 96, Issue:9 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Cell Survival; Cytarabine; Daunorubicin; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-3; Leukemia, Megakaryoblastic, Acute; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Stem Cell Factor; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine	2001
Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed : Medscape general medicine, 2001, Sep-07, Volume: 3, Issue:5 Topics: Adult; Benzamides; Drug Therapy, Combination; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Male; Piperazines; Pyrimidines	2001
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Enzyme Inhibitors; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Immunosuppression Therapy; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Transfusion; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous	2001
Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia, 2002, Volume: 16, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Benzamides; Combined Modality Therapy; Enzyme Inhibitors; Exons; Humans; Hydroxyurea; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytes; Male; Middle Aged; Molecular Sequence Data; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Spleen; Splenectomy; Tumor Cells, Cultured	2002
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia research, 2002, Volume: 26, Issue:9 Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modality Therapy; Consciousness Disorders; Cytarabine; Drug Resistance, Multiple; Enzyme Inhibitors; Fatal Outcome; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Indomethacin; Infarction; Male; Middle Aged; Mitral Valve Stenosis; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Splenectomy	2002
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. Deutsche medizinische Wochenschrift (1946), 2002, Oct-18, Volume: 127, Issue:42 Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Histidine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Selection, Genetic; Tyrosine	2002
[Chronic myeloid leukemia--case report]. Deutsche medizinische Wochenschrift (1946), 2002, Dec-06, Volume: 127, Issue:49 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Cytarabine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Piperazines; Prognosis; Pyrimidines; Remission Induction	2002
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia. Leukemia & lymphoma, 2002, Volume: 43, Issue:12 Topics: Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines	2002
Polycythemia vera responds to imatinib mesylate. The American journal of the medical sciences, 2003, Volume: 325, Issue:3 Topics: Adult; Benzamides; Blood Platelets; Enzyme Inhibitors; Female; Hematocrit; Humans; Hydroxyurea; Imatinib Mesylate; Middle Aged; Piperazines; Polycythemia Vera; Pyrimidines	2003
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Coronary Disease; Drug Eruptions; Dyspnea; Enzyme Inhibitors; Facial Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Sunlight; Ultraviolet Rays	2003
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. Haematologica, 2003, Volume: 88, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytokines; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Th1 Cells; Th2 Cells	2003
[Chronic myeloproliferative diseases. Diagnosis and therapy]. Der Internist, 2003, Volume: 44, Issue:8 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Diagnosis, Differential; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins	2003
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood, 2004, May-01, Volume: 103, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Examination; Drug Evaluation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microcirculation; Neovascularization, Pathologic; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Retrospective Studies	2004
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. International journal of hematology, 2004, Volume: 79, Issue:1 Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorubicin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxyurea; Imatinib Mesylate; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Pyrimidines; Vincristine; Zoledronic Acid	2004
C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica, 2004, Volume: 89, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Busulfan; Cell Division; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines	2004
The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scottish medical journal, 2004, Volume: 49, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Incidence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Registries; Scotland; Surveys and Questionnaires	2004
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Haematologica, 2004, Volume: 89, Issue:10 Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance; Enzyme Inhibitors; Gene Rearrangement; Humans; Hydroxyurea; Imatinib Mesylate; Leukocytosis; Male; Middle Aged; Mutant Proteins; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Splenectomy; Splenomegaly; Thrombocytopenia; Translocation, Genetic; Treatment Failure	2004
The Philadelphia translocation and pre-existing myeloproliferative disorders. British journal of haematology, 2005, Volume: 128, Issue:5 Topics: Antineoplastic Agents; Benzamides; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic	2005
Chronic myelogenous leukemia manifested as bilateral proliferative retinopathy. Archives of ophthalmology (Chicago, Ill. : 1960), 2005, Volume: 123, Issue:4 Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fluorescein Angiography; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retinal Neoplasms; Retinal Neovascularization	2005
Chronic myelogenous leukemia in accelerated phase. Archives of pathology & laboratory medicine, 2005, Volume: 129, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic	2005
Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. PharmacoEconomics, 2005, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Piperazines; Pyrimidines	2005
Philadelphia-chromosome positive thrombocythemia in a child. European journal of haematology, 2005, Volume: 75, Issue:3 Topics: Benzamides; Bone Marrow; Child; Female; Humans; Hydroxyurea; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocytosis	2005
CML clonal evolution with resistance to single agent imatinib therapy. Clinical and laboratory haematology, 2005, Volume: 27, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Trisomy	2005
Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib. Haematologica, 2005, Volume: 90 Suppl Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hydroxyurea; Imatinib Mesylate; Insulin; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction	2005
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica, 2005, Volume: 90 Suppl Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine	2005
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leukemia research, 2006, Volume: 30, Issue:9 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiomyopathies; Eosinophil Cationic Protein; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Serine Endopeptidases; Tryptases; World Health Organization	2006
Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia. American journal of hematology, 2006, Volume: 81, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Erythromelalgia; Etoposide; Female; Humans; Hydroxyurea; Imatinib Mesylate; Infarction; Interferon-alpha; Kidney; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiography	2006
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. American journal of hematology, 2006, Volume: 81, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase Inhibitors; Caspases; Celecoxib; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-1; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Pyrazoles; Pyrimidines; S Phase; Sulfonamides	2006
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement. Cancer genetics and cytogenetics, 2006, Volume: 167, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome	2006
[Two patients with hypereosinophilic syndrome]. Nederlands tijdschrift voor geneeskunde, 2006, May-27, Volume: 150, Issue:21 Topics: Adult; Benzamides; Diagnosis, Differential; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prednisone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Stem Cell Transplantation	2006
[Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature]. Orvosi hetilap, 2006, May-07, Volume: 147, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diagnosis, Differential; Humans; Hungary; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Neutrophilic, Chronic; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Treatment Outcome	2006
Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. American journal of hematology, 2006, Volume: 81, Issue:8 Topics: Aged; Benzamides; Cytogenetic Analysis; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2006
Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:12 Topics: Animals; Antineoplastic Agents; Benzamides; Biological Transport; Blood-Brain Barrier; Brain; Glioblastoma; Hydroxyurea; Imatinib Mesylate; Male; Mice; Mice, Inbred Strains; Piperazines; Pyrimidines; Rats; Rats, Wistar	2006
The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:6 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport, Active; Cell Line; Cytochrome P-450 CYP3A; Dogs; Humans; Hydroxyurea; Imatinib Mesylate; Mice; Neoplasm Proteins; Piperazines; Pyrimidines	2007
Neurofibromatosis type 2. Neurology, 2007, Mar-27, Volume: 68, Issue:13 Topics: Antineoplastic Agents; Benzamides; Cochlear Nerve; Female; Functional Laterality; Hearing Loss, Sensorineural; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Piperazines; Pyrimidines; Treatment Outcome; Vestibular Nerve	2007
Cocaine abuse may influence the response to imatinib in CML patients. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Cocaine; Cocaine-Related Disorders; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxyurea; Imatinib Mesylate; Inactivation, Metabolic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Liver; Male; Piperazines; Pyrimidines; Substrate Specificity	2007
[The hypereosinophilic syndrome: case report]. Annales Academiae Medicae Stetinensis, 2006, Volume: 52 Suppl 2 Topics: Adult; Benzamides; Bone Marrow; Diagnosis, Differential; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferons; Lymphatic Diseases; Male; Methylprednisolone; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Treatment Outcome	2006
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells. Leukemia & lymphoma, 2007, Volume: 48, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; Hematopoietic Stem Cells; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
[Imatinib therapy in chronic myeloid leukemia]. Orvosi hetilap, 2008, Aug-10, Volume: 149, Issue:32 Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome	2008
Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Current clinical pharmacology, 2008, Volume: 3, Issue:3 Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Isoenzymes; Male; Middle Aged; Piperazines; Pyrimidines; Seizures; Young Adult	2008
Is imatinib safe during pregnancy? Leukemia research, 2009, Volume: 33, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Pyrimidines	2009
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leukemia research, 2009, Volume: 33, Issue:8 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Proteins; Time Factors	2009
Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. Journal of neuro-oncology, 2009, Volume: 93, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Neurosurgical Procedures; Piperazines; Positron-Emission Tomography; Pyrimidines	2009
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. American journal of hematology, 2009, Volume: 84, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles; Treatment Failure	2009
A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line. Leukemia & lymphoma, 2009, Volume: 50, Issue:8 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chimera; Chromosomes, Human, Pair 9; Chromosomes, Human, X; Chromosomes, Human, Y; Disease Progression; Fertility; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidental Findings; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Piperazines; Polycythemia Vera; Pyrimidines; Sex Chromosome Aberrations; Trisomy	2009
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell cycle (Georgetown, Tex.), 2009, Nov-01, Volume: 8, Issue:21 Topics: 5-Lipoxygenase-Activating Proteins; Animals; Benzamides; Carrier Proteins; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipoxygenase Inhibitors; Membrane Proteins; Mice; Mice, Knockout; Myeloproliferative Disorders; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2009
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. American journal of hematology, 2009, Volume: 84, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Bone Marrow; Cladribine; Dioxygenases; DNA Mutational Analysis; DNA-Binding Proteins; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Janus Kinase 2; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Prednisone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult	2009
On being metachromatic: mystique and misunderstanding in mastocytosis. American journal of hematology, 2009, Volume: 84, Issue:12 Topics: Benzamides; Cell Shape; Cladribine; Cytoplasmic Granules; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Mast Cells; Mastocytosis, Systemic; Piperazines; Pyrimidines; Retrospective Studies; Staining and Labeling	2009
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:6 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Chemokine CCL17; Child; Cyclosporine; Drug Therapy, Combination; Eosinophils; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Interleukin-5; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Tryptases; Young Adult	2009
[Case of pediatric chronic myeloid leukemia with bilateral visual loss onset]. Nippon Ganka Gakkai zasshi, 2010, Volume: 114, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome; Vision, Low	2010
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur	2010
Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line. Experimental biology and medicine (Maywood, N.J.), 2010, Volume: 235, Issue:11 Topics: Antigens, Surface; Benzamides; beta-Globins; Butyrates; Cell Differentiation; Cell Line, Tumor; Erythroid Precursor Cells; Fetal Hemoglobin; gamma-Globins; Gene Expression; Humans; Hydroxamic Acids; Hydroxylamines; Hydroxyurea; Imatinib Mesylate; K562 Cells; Piperazines; Pyrimidines; Quinolines; RNA, Messenger; Signal Transduction; Transcription Factors; Vorinostat	2010
[Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia]. Zhonghua fu chan ke za zhi, 2010, Volume: 45, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Infant, Low Birth Weight; Infant, Newborn; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy Trimester, Third; Prognosis; Pyrimidines; Retrospective Studies	2010
Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clinical & developmental immunology, 2010, Volume: 2010 Topics: Adult; Antineoplastic Agents; Benzamides; C-Reactive Protein; Complement System Proteins; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunity, Innate; Immunoglobulins; Immunologic Factors; Interferon-alpha; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles; Treatment Outcome	2010
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European journal of haematology, 2011, Volume: 86, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cytarabine; DNA Damage; Drug Synergism; Gene Expression; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Piperazines; Pyrimidines; Tumor Stem Cell Assay	2011
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism. Cytogenetic and genome research, 2011, Volume: 132, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-gamma; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic	2011
Metastatic uterine leiomyosarcoma and eosinophilia. Obstetrics and gynecology, 2011, Volume: 117, Issue:2 Pt 2 Topics: Antineoplastic Agents; Benzamides; Dyspnea; Eosinophilia; Fatal Outcome; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Middle Aged; Piperazines; Prednisone; Pyrimidines; Splenic Neoplasms; Uterine Neoplasms	2011
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. American journal of hematology, 2011, Volume: 86, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles	2011
Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; DNA Probes; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retrospective Studies; Translocation, Genetic	2012
Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. American journal of hematology, 2011, Volume: 86, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Medication Adherence; Middle Aged; Pathology, Molecular; Piperazines; Pyrimidines; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult	2011
Chronic myelogenous leukemia in the chronic phase with lymph node swelling which represented extramedullary involvement composed of cells at different stages of maturation. Rinsho byori. The Japanese journal of clinical pathology, 2011, Volume: 59, Issue:4 Topics: Benzamides; Blast Crisis; Fatal Outcome; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymph Nodes; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2011
Steroid-unresponsive hypereosinophilic syndrome. Annals of tropical paediatrics, 2011, Volume: 31, Issue:3 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Child; Drug Therapy, Combination; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Piperazines; Prednisolone; Pyrimidines; Steroids; Treatment Outcome	2011
Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response. Blood, 2011, Nov-10, Volume: 118, Issue:19 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles	2011
Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia. The British journal of oral & maxillofacial surgery, 2012, Volume: 50, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Follow-Up Studies; Gingival Neoplasms; Humans; Hydroxyurea; Hypopharyngeal Neoplasms; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Neoplasms; Neoplasms, Second Primary; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tongue Neoplasms	2012
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012, May-01, Volume: 125, Issue:17 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome	2012
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Molecular diagnosis & therapy, 2012, Jun-01, Volume: 16, Issue:3 Topics: Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Disease Progression; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2012
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2012, Volume: 16, Issue:4 Topics: Adolescent; Allopurinol; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Therapy, Combination; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retina; Retinal Neoplasms; Retinal Vein Occlusion; Vision Disorders; Visual Acuity	2012
Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Molecular cancer therapeutics, 2013, Volume: 12, Issue:6 Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, abl; HSP90 Heat-Shock Proteins; Humans; Hydroxyurea; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Survivin	2013
Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase. BMJ case reports, 2013, Apr-15, Volume: 2013 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sarcoma, Myeloid; Skin Neoplasms	2013
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera. Acta haematologica, 2015, Volume: 133, Issue:1 Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2015
Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog. The Journal of veterinary medical science, 2014, Volume: 76, Issue:11 Topics: Animals; Benzamides; Cerebellar Neoplasms; Dog Diseases; Dogs; Fatal Outcome; Hydroxyurea; Imatinib Mesylate; Male; Meningioma; Piperazines; Prednisolone; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome	2014
Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience. Journal of the Egyptian National Cancer Institute, 2015, Volume: 27, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult	2015
Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia. Pediatric transplantation, 2016, Volume: 20, Issue:1 Topics: Adolescent; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Primary Ovarian Insufficiency; Transplantation Conditioning; Treatment Outcome; Young Adult	2016
Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Splenomegaly; Survival Rate; Treatment Outcome; Young Adult	2015
Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients. Journal of proteome research, 2016, 09-02, Volume: 15, Issue:9 Topics: Amino Acids; Citric Acid Cycle; Drug Monitoring; Glycolysis; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Metabolome; Metabolomics; Plasma; Protein Kinase Inhibitors	2016
Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2017, Mar-01, Volume: 34, Issue:1 Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Hydroxyurea; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome	2017
Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy. Breast cancer (Tokyo, Japan), 2017, Volume: 24, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mammography; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Sentinel Lymph Node Biopsy; Ultrasonography, Doppler, Color	2017
CASE OF DEVELOPMENT OF NON-HODGKIN'S MALIGNANT LYMPHOMA ON THE BACKGROUND OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WHO SUFFERED OF THE CHORNOBYL ACCIDENT. Problemy radiatsiinoi medytsyny ta radiobiolohii, 2018, Volume: 23 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chernobyl Nuclear Accident; Cyclophosphamide; Doxorubicin; Environmental Exposure; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell; Middle Aged; Prednisone; Radiation Exposure; Radiation, Ionizing; Treatment Outcome; Ukraine; Vincristine	2018
Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role. Asian Pacific journal of cancer prevention : APJCP, 2019, Dec-01, Volume: 20, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Sectional Studies; Female; Humans; Hydroxyurea; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Malondialdehyde; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Young Adult	2019
Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Progression-Free Survival; Treatment Outcome; Yemen; Young Adult	2020
[Hypereosinophilic syndromes]. La Revue du praticien, 2019, Volume: 69, Issue:7 Topics: Eosinophils; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate	2019
Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy. International journal of hematology, 2020, Volume: 112, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Substitution; Endothelium, Vascular; Humans; Hydroxyurea; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome	2020
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients. Recent patents on anti-cancer drug discovery, 2021, Volume: 16, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Developing Countries; Female; Fusion Proteins, bcr-abl; Health Services Accessibility; Humans; Hydroxyurea; Imatinib Mesylate; L-Lactate Dehydrogenase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Uric Acid; Young Adult	2021